Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07129759) titled 'Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Lumos Pharma
Condition:
Growth Hormone Deficiency (GHD)
Intervention:
Drug: LUM-201
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 2026
Target Sample Size: 150
To know more, visit https://clinicaltrials.gov/ct2/show/NCT07129759
Published by HT Digital Content Services with permission f...